Works Cited

1. Centers for Disease Control and Prevention. Mental Health. Available at https://www.cdc.gov/mentalhealth/index.htm. Last accessed February 11, 2021.

2. Reeves WC, Strine TW, Pratt LA, et al. Mental illness surveillance among adults in the United States. MMWR. 2011;60(3):1-32.

3. Clark DB. Dental care for the patient with bipolar disorder. J Can Dent Assoc. 2003;69(1):20-24.

4. Durand MV, Barlow DH. Essentials of Abnormal Psychology. 8th ed. Boston, MA: Cengage; 2019.

5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.

6. University of Florida Health. Bipolar Disorder. Available at https://ufhealth.org/bipolar-disorder. Last accessed February 11, 2021.

7. National Institute of Mental Health. Bipolar Disorder. Available at https://www.nimh.nih.gov/health/topics/bipolar-disorder/index.shtml. Last accessed February 11, 2021.

8. Grohol JM. How Long is a Typical Bipolar Episode? Available at https://psychcentral.com/blog/how-long-is-a-typical-bipolar-episode#1. Last accessed February 11, 2021.

9. Montgomery DB. NICE guidelines for investigating efficacy in bipolar disorder. Eur Neuropsychopharmacol. 2001;11(1):79-88.

10. Nurnberger JL, Gershon ES. The genetics of affective disorders. In: Friedman E (ed). Depression and Antidepressants and Implications for Cause and Treatment. New York, NY: Raven Press; 1983: 75-98.

11. Fattal O, Budur K, Vaughan AJ, Franco K. Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics. 2006;47(1):1-7.

12. Lewitzka U, Severus E, Bauer R, Ritter P, Müller-Oerlinghausen B, Bauer M. The suicide prevention effect of lithium: more than 20 years of evidence-a narrative review. Int J Bipolar Disord. 2015;3(1):32.

13. Wynn RL, Meiller TF, Crossley HL. Drug Information Handbook for Dentistry. 21st ed. Hudson, OH: Lexi-Comp; 2015.

14. American Dental Association. ADA/PDR Guide to Dental Therapeutics. 5th ed. Chicago, IL: American Dental Association; 2009.

15. Page MM. Psychotropic drugs and dentistry. Aust Prescr. 2007;30:98-101.

16. National Institute of Mental Health. Statistics. Available at https://www.nimh.nih.gov/health/statistics/index.shtml. Last accessed February 12, 2021.

17. Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. An Update of the 2007 Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

18. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629-640.

19. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160-174.

20. Strine TW, Mokdad AH, Balluz LS, et al. Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv. 2008;59:1383-1390.

21. Chapman DP, Perry GS, Strine TW. The vital link between chronic disease and depressive disorders. Prev Chronic Dis. 2005;2:A14.

22. Gursky TM, Haight R, Hardwig J, et al. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. 17th ed. Available at https://www.icsi.org/wp-content/uploads/2019/01/Depr.pdf. Last accessed February 12, 2021.

23. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Washington, DC: American Psychiatric Publishing, Inc.; 2010. (Reaffirmed October 31, 2015.)

24. Bartlett D. Caring for the Poisoned Patient. Sacramento, CA: NetCE; 2018.

25. Verma A, Yadav S, Sachdeva A. Dental consequences and management in patients with major depressive disorder. Journal of Innovative Dentistry. 2011;1(3).

26. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737-748.

27. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry. 2009;194(6):483-490.

28. Malamed SF. Handbook of Local Anesthesia. 5th ed. St. Louis, MO: Mosby; 2016.

29. National Institute of Mental Health. The Numbers Count: Mental Disorders in America. Available at http://www.lb7.uscourts.gov/documents/12-cv-1072url2.pdf. Last accessed February 12, 2021.

30. National Institute of Mental Health. Anxiety Disorders. Available at https://www.nimh.nih.gov/health/topics/anxiety-disorders/index.shtml. Last accessed February 12, 2021.

31. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439.

32. Psychiatry Online. Highlights of Changes from DSM-IV-TR to DSM-5. Available at https://dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425596.changes. Last accessed February 12, 2021.

33. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.

34. Anxiety and Depression Association of America. Clinical Practice Review for GAD. Available at https://adaa.org/resources-professionals/practice-guidelines-gad. Last accessed February 12, 2021.

35. National Institute of Mental Health. Panic Disorder. Available at https://www.nimh.nih.gov/health/statistics/panic-disorder.shtml. Last accessed February 12, 2021.

36. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H-U. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184.

37. Marques L, Robinaugh DJ, LeBlanc NJ, Hinton D. Cross-cultural variations in the prevalence and presentation of anxiety disorders. Expert Rev Neurother. 2011;11(2):313-322.

38. Craske MG, Tsao JC. Assessment and treatment of nocturnal panic attacks. Sleep Med Rev. 2005;9(3):173-184.

39. Katerndahl DA. Chest pain and its importance in patients with panic disorder: an updated literature review. Prim Care Companion J Clin Psychiatry. 2008;10(5):376-383.

40. Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF 3rd. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. Focus. 2014;12(3):347-358.

41. Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-192.

42. Prescriber's Digital Reference. Panic Disorder Treatment. Available at https://www.pdrhealth.com/diseases/panic-disorder/treatment. Last accessed February 11, 2021.

43. Curtis EK. Meth mouth: a review of methamphetamine abuse and its oral manifestations. Gen Dent. 2006;54(2):125-129.

44. American Dental Association. Meth Mouth: How Methamphetamine Use Affects Dental Health. Available at https://www.mouthhealthy.org/en/az-topics/m/meth-mouth. Last accessed February 12, 2021.

45. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.

46. Stinson FS, Dawson DA, Chou SP, et al. The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 2007;37(7):1047-1059.

47. Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.

48. Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev. 2008;28(6):1021-1037.

49. International Society for Traumatic Stress Studies. The ISTSS Expert Consensus Treatment Guidelines for Complex PTSD in Adults. Available at http://www.istss.org/ISTSS_Main/media/Documents/ComplexPTSD.pdf. Last accessed February 12, 2021.

50. Nygaard E, Wentzel-Larsen T, Hussain A, Heir T. Family structure and posttraumatic stress reactions: a longitudinal study using multilevel analyses. BMC Psychiatry. 2011;11:195.

51. Heir T, Piatigorsky A, Weisaeth L. Longitudinal changes in recalled perceived life threat after a natural disaster. Br J Psychiatry. 2009;194(6):510-514.

52. Neria Y, Olfson M, Gameroff MJ, et al. Long-term course of probable PTSD after the 9/11 attacks: a study in urban primary care.J Trauma Stress. 2010;23(4):474-482.

53. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821-1829.

54. National Institute of Mental Health. Schizophrenia. Available at https://www.nimh.nih.gov/health/publications/schizophrenia/index.shtml. Last accessed February 12, 2021.

55. Clark DB. Dental care for the patient with schizophrenia. Can J Dent Hygiene. 2008;42(1):17-24.

56. National Alliance on Mental Illness. Types of Medication. Available at https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication. Last accessed February 11, 2021.

57. National Alliance on Mental Illness. Tardive Dyskinesia. Available at https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Last accessed February 12, 2021.

58. Collingwood J. Coping with Atypical Antipsychotic Side Effects. Available at https://psychcentral.com/lib/coping-with-atypical-antipsychotic-side-effects. Last accessed February 12, 2021.

59. Clark DB. Dental care for the patient with schizophrenia. Can J Dent Hygiene. 2008;42(1):17-24.

60. Little JW, Miller CS, Rhodus NL. Dental Management of the Medically Compromised Patient. 9th ed. St. Louis, MO: Mosby Elsevier; 2018.

61. Patton L, Glick M. The ADA Practical Guide to Patients with Medical Conditions. 2nd ed. Hoboken, NJ: John Wiley and Sons; 2016.

62. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry. 2004;184:470-476.

63. Oyama O, Paltoo C, Greengold J. Somatoform disorders. Am Fam Physician. 2007;76(9):1333-1338.

64. Tomar BI, Bhatia NK, Kumar P, Bhatia MS, Shah RJ. The psychiatric and dental interrelationship. Delhi Psychiatry Journal. 2011;14(1):138-142.

65. John Hopkins Medicine. Trigeminal Neuralgia. Available at https://www.hopkinsmedicine.org/health/conditions-and-diseases/trigeminal-neuralgia. Last accessed February 11, 2021.

66. American Society of Addiction Medicine. Definition of Addiction. Available at https://www.asam.org/quality-practice/definition-of-addiction. Last accessed February 12, 2021.

67. Yaksh T, Wallace M. Opioids, analgesia, and pain management. In: Brunton L, Hilal-Dandan R, Knollmann BC (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York, NY: McGraw-Hill; 2017: 355-386.

68. Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users.Drug Alcohol Depend. 2007;87(1):98-102.

69. National Cancer Institute. Cancer Pain. Available at https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq. Last accessed February 12, 2021.

70. U.S. Food and Drug Administration. Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS). Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_opioids_2015.06.26_REMS_document.pdf. Last accessed February 12, 2021.

71. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972.

72. Schwartz RH. Adolescent heroin use: a review. Pediatrics. 1998;102(6):1461-1466.

73. Wasan AD, Correll DJ, Kissin I, O'Shea S, Jamison RN. Iatrogenic addiction in patients treated for acute or subacute pain: a systematic review. J Opioid Manag. 2006;2(1):16-22.

74. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-107.

75. McCabe SE, West BT, Morales M, Cranford JA, Boyd CJ. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction. 2007;102(12):1920-1930.

76. The Partnership for a Drug-Free America. 2012 Partnership Attitude Tracking Study: Teens and Parents. Available at https://drugfree.org/wp-content/uploads/2013/04/PATS-2012-FULL-REPORT2.pdf. Last accessed February 12, 2021.

77. Reynolds WR, Schwarz ES. Dentists' current and optimal opioid prescribing practices: a proactive review. Mo Med. 2019;116(5):347-350.

78. Nack B, Haas SE, Portnof J. Opioid use disorder in dental patients: the latest on how to identify, treat, refer and apply laws and regulations in your practice. Anesth Prog. 2017;64(3):178-187.

79. American Dental Association. Opioid Crisis. Available at https://www.ada.org/en/advocacy/advocacy-issues/opioid-crisis. Last accessed February 12, 2021.

80. McFarland KK, Giannini PJ, Fung EYK. Addiction and Oral Health Care. Available at https://decisionsindentistry.com/article/addiction-oral-health-care. Last accessed February 12, 2021.

81. Hser YI, Evans E, Huang YC. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005;28(1):77-85.

82. Drug Enforcement Administration. Benzodiazepines. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/benzo.pdf. Last accessed February 12, 2021.

83. Weissheimer T, Schwengber HE, Gerzson AS, Neto AM. Benzodiazepines for conscious sedation in the dental office. Stomatos. 2016; 22(42).

84. O'Keefe Osborn C. How Long Does Withdrawal From Benzodiazepines Last? Available at https://www.verywellmind.com/benzodiazepine-withdrawal-4588452. Last accessed February 12, 2021.

85. Gold J. Approaches to managing benzodiazepines. Pharmacy Today. 2020;26(3):P41-P54.

86. Schuckit MA. Drug and Alcohol Abuse: A Clinical Guide to Diagnosis and Treatment. 6th ed. New York, NY: Springer; 2010.

87. Sullivan MA, Rudnik-Levin F. Attention deficit/hyperactivity disorder and substance abuse: diagnostic and therapeutic considerations. Ann NY Acad Sci. 2001;931:251-270.

88. National Institute on Alcohol Abuse and Alcoholism. Alcohol Facts and Statistics. Available at https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics. Last accessed February 12, 2021.

89. Moses S. Lab Markers of Malnutrition. Available at https://fpnotebook.com/Pharm/Lab/LbMrkrsOfMlntrtn.htm. Last accessed February 12, 2021.

90. Van den Berg H, van der Gaag M, Hendriks H. Influence of lifestyle on vitamin bioavailability. Int J Vitam Nutr Res. 2002;72(1):53-59.

91. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alcohol. 2000;35(1):2-7.

92. Zhang P, Bagby GJ, Happel KI, Summer WR, Nelson S. Pulmonary host defenses and alcohol. Front Biosci. 2002;7:d1314-d1330.

93. Vertava Health. Bone Marrow Suppression from Alcohol Abuse. Available at https://vertavahealth.com/alcohol/bone-marrow-suppression. Last accessed February 12, 2021.

94. Malamed SF. Articaine 20 Years Later. Available at https://www.dentallearning.net/articaine-20-years-later. Last accessed February 12, 2021.

95. Gómez-Moreno G, Guardia J, Cutando A. Interaction of paracetamol in chronic alcoholic patients: importance for odontologists. Med Oral Patol Oral Cir Bucal. 2008;13(4):E235-E238.

96. Girre C, Hispard E, Palombo S, N'Guyen C, Dally S. Increased metabolism of acetaminophen in chronically alcoholic patients. Alcohol Clin Exp Res. 1993;17(1):170-173.

97. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med. 1986;104(3):399-404.

98. Black M. Acetaminophen hepatotoxicity. Ann Rev Med. 1984;35:577-593.

99. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients: a multicenter randomized study. BMC Med. 2007;30:13.

100. U.S. Food and Drug Administration. Acetaminophen Prescription Combination Drug Products with More than 325 mg: FDA Statement: Recommendation to Discontinue Prescribing and Dispensing. Available at https://wayback.archive-it.org/7993/20170406123735/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm381650.htm. Last accessed February 12, 2021.

101. Centers for Disease Control and Prevention. Consumption of cigarettes and combustible tobacco—United States, 2000–2015. MMWR. 2016;65(48):1357-1363.

102. Centers for Disease Control and Prevention. Smokeless Tobacco Use in the United States. Available at https://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/use_us/index.htm. Last accessed February 12, 2021.

103. Lipari RN, Van Horn SL. Trends in Smokeless Tobacco Use and Initiation: 2002 to 2014. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2017.

104. Wang TW, Asman K, Gentzke AS, et al. Tobacco product use among adults—United States, 2017. MMWR. 2018;67(44):1225-1232.

105. Wong LS, Green HM, Feugate JE, Yadav M, Nothnangel EA, Martins-Green M. Effects of "second-hand" smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling. BMC Cell Biol. 2004;5(1):13.

106. Yuan H, Wong LS, Bhattacharya M. The effects of second-hand smoke on biological processes important in atherogenesis.BMC Cardiovasc Disord. 2007;7:1.

107. Centers for Disease Control and Prevention. Lung Cancer: What Are the Risk Factors for Lung Cancer? Available at https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm. Last accessed February 12, 2021.

108. Centers for Disease Control and Prevention. Tobacco Use by Geographic Region. Available at https://www.cdc.gov/tobacco/disparities/geographic/index.htm. Last accessed February 12, 2021.

109. Centers for Disease Control and Prevention. Smokeless Tobacco Use in the United States. Available at https://www.cdc.gov/tobacco/data_statistics/fact_sheets/smokeless/use_us/index.htm. Last accessed February 12, 2021.

110. U.S. Food and Drug Administration. Rural Tobacco Use: Research and Interventions. Available at https://www.fda.gov/media/133281/download. Last accessed February 12, 2021.

111. American Cancer Society. Health Risks of Smokeless Tobacco. Available at https://www.cancer.org/cancer/cancer-causes/tobacco-and-cancer/smokeless-tobacco.html. Last accessed February 12, 2021.

112. Lunell E, Bergström M, Antoni G, Långström B, Nordberg A. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clin Pharmacol Ther. 1996;59(5):593-594.

113. Jarvis MJ. Why people smoke. BMJ. 2004;328(7434):277-279.

114. Couch ET, Chaffee BW, Gansky SA and Walsh MM. The changing tobacco landscape: what dental professionals need to know.J Am Dent Assoc 2016;147(7):561-9.

115. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.

116. Al Feghali KA, Ghanem AI, Burmeister C, et al. Impact of smoking on pathological features in oral cavity squamous cell carcinoma. J Cancer Res Ther. 2019;15(3):582-588.

117. American Dental Association. Tobacco Use and Cessation. Available at https://www.ada.org/en/member-center/oral-health-topics/tobacco-use-and-cessation. Last accessed February 12, 2021.

118. Yard D. The Role of Clinicians in Smoking Cessation. Available at https://www.clinicaladvisor.com/home/features/the-role-of-clinicians-in-smoking-cessation. Last accessed February 12, 2021.

119. Leone FT, Zhang Y, Evers-Casey S, et al. Initiating pharmacologic treatment in tobacco-dependent adults: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;202(2):e5-e31.

120. Doggrell SA. Which is the best primary medication for long-term smoking cessation—nicotine replacement therapy, bupropion or varenicline? Expert Opin Pharmacother. 2007;8(17):2903-2915.

121. Zhong Z, Zhao S, Zhao Y, Xia S. Combination therapy of varenicline and bupropion in smoking cessation: a meta-analysis of the randomized controlled trials. Compr Psychiatry. 2019;95:152125.

122. Prochaska JO, Redding CA, Evers KE. The transtheoretical model and stages of change. In: Glanz K, Rimer BK, Viswanath K (eds). Health Behavior and Health Education. 4th ed. San Francisco, CA: Jossey-Bass; 2008: 97-121.

123. Global Drug Survey. Global Drug Survey: 2020 Executive Summary. Available at https://www.globaldrugsurvey.com/wp-content/uploads/2021/01/GDS2020-Executive-Summary.pdf. Last accessed February 12, 2021.

124. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1-2):1-25.

125. Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend. 2005;80(2):147-159.

126. De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(2):1479-1494.

127. Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghampton, NY: The Hathworth Press; 2002.

128. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130(1-3):216-221.

129. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-130.

130. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2012;10(4):487-492.

131. Grotenhermen F. Review of therapeutic effects. In: Grotenhermen F, Russo E (eds). Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. New York, NY: Routledge; 2002: 123-142.

132. Ribeiro LIG, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Primary Care Respiratory Medicine. 2016;26:16071.

133. Portillo KM, Sanderson TR, Gurenlian J. Oral Health Care for Marijuana Users. Available at https://decisionsindentistry.com/article/oral-health-care-marijuana-users. Last accessed February 12, 2021.

134. Joshi S, Ashley M. Cannabis: a joint problem for patients and the dental profession. Br Dent J. 2016;220(11):597-601.

135. Ahrens AGMS, Bressi T. Marijuana as promoter for oral cancer? More than a suspect. Addictive Disorders & Their Treatment. 2007;6(3):117-119.

136. Faustino ISP, Gonzalez-Arriagada WA, Cordero-Torres K, Lopes MA. Candidiasis of the tongue in cannabis users: a report of 2 cases. Gen Dent. 2020;68(5):66-68.

137. Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR. Vaccines for cocaine abuse. Hum Vaccin. 2009;5(4):194-199.

138. National Institute on Drug Abuse. What Is Cocaine? Available at https://www.drugabuse.gov/publications/research-reports/cocaine/what-cocaine. Last accessed February 12, 2021.

139. Ries RK, Fiellin DA, Miller SC, Saitz R. Principles of Addiction Medicine. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2014.

140. Australian Government Department of Health. Pharmacology of Cocaine. Available at https://www1.health.gov.au/internet/publications/publishing.nsf/Content/drugtreat-pubs-modpsy-toc~drugtreat-pubs-modpsy-2~drugtreat-pubs-modpsy-2-3~drugtreat-pubs-modpsy-2-3-pcoc. Last accessed February 12, 2021.

141. Brownlow HA, Pappachan J. Pathophysiology of cocaine abuse. Eur J Anaesthesiol. 2002;19(6):395-414.

142. Prakash A, Das G. Cocaine and the nervous system. Int J Clin Pharmacol Ther Toxicol. 1993;31(12):575-581.

143. Cornish JW, O'Brien CP. Crack cocaine abuse: an epidemic with many public health consequences. Annu Rev Public Health. 1996;17:259-273.

144. Burnett LB. Cocaine Toxicity. Available at https://emedicine.medscape.com/article/813959-overview. Last accessed February 12, 2021.

145. Peters M. The Difference Between Meth and Cocaine. Available at https://lannarehab.com/blog/the-difference-between-meth-and-cocaine. Last accessed February 12, 2021.

146. Chapparro-Gonzalez NT, Fox-Delgado MA, Pineda-Chaparro RT, Perozo-Ferrer BI, Díaz-Amell AR, Torres V. Oral and maxillofacial manifestations in patients with drug addiction. Odontoesstomatologia. 2018;20(32):24-31.

147. Teoh L, Moses G, McCullough MJ. Oral manifestations of illicit drug use. Aust Dent J. 2019;64(3):213-22.

148. Nassar P, Ouanounou A. Cocaine and methamphetamine: pharmacology and dental implications. CanJ Dent Hyg. 2020;54(2):75-82.

149. Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: a placebo-controlled pilot study.Int Clinl Psychopharmacol. 2005;20(5):253-256.

150. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry. 2005;13(3):141-154.

151. Boles SM, Miotto K. Substance abuse and violence: a review of the literature. Aggress Violent Behav. 2003;8(2):155-174.

152. Anglin MD, Burke C, Perrochet B, Stamper E, Dawud-Noursi S. History of the methamphetamine problem. J Psychoactive Drugs. 2000;32(2):137-141.

153. Degenhardt L, Topp L. "Crystal meth" use among polydrug users in Sydney's dance party subculture: characteristics, use patterns and associated harms. Int J Drug Policy. 2003;14(1):17-24.

154. Randall JR, Walld R, Finlayson G, Sareen J, Martens PJ, Bolton JM. Acute risk of suicide and suicide attempts associated with recent diagnosis of mental disorders: a population-based, propensity score-matched analysis. Can J Psychiatry. 2014;59(10):531-538.

155. American Association of Suicidology. Facts and Statistics. Available at https://suicidology.org/facts-and-statistics. Last accessed February 12, 2021.

Evidence-Based Practice Recommendations Citations

1. Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: a report of the American Dental Association. JADA. 2017;148(10):P712-P727. Available at https://jada.ada.org/article/S0002-8177(17)30701-8/fulltext?dgcid=PromoSpots_EBDsite_Oralcancer. Last accessed February 15, 2021.

2. Management of Substance Use Disorders Work Group. VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. Washington, DC: Department of Veterans Affairs, Department of Defense; 2015. Available at https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf. Last accessed February 15, 2021.



Privacy Policy
Copyright © 2021 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.